JP2018529743A5 - - Google Patents

Download PDF

Info

Publication number
JP2018529743A5
JP2018529743A5 JP2018517444A JP2018517444A JP2018529743A5 JP 2018529743 A5 JP2018529743 A5 JP 2018529743A5 JP 2018517444 A JP2018517444 A JP 2018517444A JP 2018517444 A JP2018517444 A JP 2018517444A JP 2018529743 A5 JP2018529743 A5 JP 2018529743A5
Authority
JP
Japan
Prior art keywords
pyrazolo
pyridine
carboxamide
phenyl
cyclobutyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018517444A
Other languages
English (en)
Japanese (ja)
Other versions
JP6779992B2 (ja
JP2018529743A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/056029 external-priority patent/WO2017060874A1/en
Publication of JP2018529743A publication Critical patent/JP2018529743A/ja
Publication of JP2018529743A5 publication Critical patent/JP2018529743A5/ja
Application granted granted Critical
Publication of JP6779992B2 publication Critical patent/JP6779992B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018517444A 2015-10-09 2016-10-07 N−スルホニル化ピラゾロ[3,4−b]ピリジン−6−カルボキサミドおよび使用法 Active JP6779992B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562239647P 2015-10-09 2015-10-09
US62/239,647 2015-10-09
US201662309794P 2016-03-17 2016-03-17
US62/309,794 2016-03-17
PCT/IB2016/056029 WO2017060874A1 (en) 2015-10-09 2016-10-07 N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use

Publications (3)

Publication Number Publication Date
JP2018529743A JP2018529743A (ja) 2018-10-11
JP2018529743A5 true JP2018529743A5 (https=) 2019-11-14
JP6779992B2 JP6779992B2 (ja) 2020-11-04

Family

ID=57209654

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018517444A Active JP6779992B2 (ja) 2015-10-09 2016-10-07 N−スルホニル化ピラゾロ[3,4−b]ピリジン−6−カルボキサミドおよび使用法

Country Status (32)

Country Link
US (4) US9890158B2 (https=)
EP (1) EP3359541B1 (https=)
JP (1) JP6779992B2 (https=)
KR (1) KR20180083323A (https=)
CN (1) CN108513574B (https=)
AU (1) AU2016333856C1 (https=)
BR (1) BR112018007161B1 (https=)
CA (1) CA3001096A1 (https=)
CL (1) CL2018000911A1 (https=)
CO (1) CO2018003716A2 (https=)
CR (1) CR20180215A (https=)
CY (1) CY1123545T1 (https=)
DK (1) DK3359541T3 (https=)
EC (1) ECSP18032223A (https=)
ES (1) ES2829636T3 (https=)
HR (1) HRP20201618T1 (https=)
HU (1) HUE051067T2 (https=)
IL (1) IL258553A (https=)
LT (1) LT3359541T (https=)
MX (1) MX379276B (https=)
NZ (1) NZ741223A (https=)
PE (1) PE20181348A1 (https=)
PH (1) PH12018500765B1 (https=)
PL (1) PL3359541T3 (https=)
PT (1) PT3359541T (https=)
RU (1) RU2724345C2 (https=)
SG (1) SG11201802932VA (https=)
SI (1) SI3359541T1 (https=)
TW (1) TWI720032B (https=)
UY (1) UY36943A (https=)
WO (1) WO2017060874A1 (https=)
ZA (1) ZA201802976B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS59111B1 (sr) 2014-08-21 2019-09-30 Boehringer Ingelheim Int Nova jedinjenja spiro[3h-indol-3,2´-pirolidin]-2(1h)-ona i derivati kao mdm2-p53 inhibitori
RU2724345C2 (ru) * 2015-10-09 2020-06-23 Галапагос Нв N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ
KR20240158360A (ko) 2015-10-09 2024-11-04 베링거 인겔하임 인터내셔날 게엠베하 Mdm2-p53 억제제로서의 스피로[3h-인돌-3,2'-피롤리딘]-2(1h)-온 화합물 및 유도체
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
EP3558982A1 (en) 2016-12-20 2019-10-30 AbbVie S.À.R.L. Deuterated cftr modulators and methods of use
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
US10988454B2 (en) * 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2019193062A1 (en) 2018-04-03 2019-10-10 Abbvie S.Á.R.L Substituted pyrrolidines and their use
GB201905711D0 (en) * 2019-04-24 2019-06-05 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
EP3747882A1 (en) 2019-06-03 2020-12-09 AbbVie Overseas S.à r.l. Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
CN114761383A (zh) * 2019-06-12 2022-07-15 诺瑟拉有限公司 磺酰胺衍生物及其用途
TW202115014A (zh) 2019-07-12 2021-04-16 美商奧佛麥德公司 用於治療囊腫纖維化之化合物
WO2021028323A1 (en) * 2019-08-09 2021-02-18 Idorsia Pharmaceuticals Ltd (2-acetamidyl)thio-beta-d-galactopyranoside derivatives
PH12022551119A1 (en) 2019-12-10 2023-08-23 Hoffmann La Roche New methylquinazolinone derivatives
RS65962B1 (sr) 2020-05-08 2024-10-31 Halia Therapeutics Inc Inhibitori nek7 kinaze
EP4161933A1 (en) 2020-06-08 2023-04-12 Halia Therapeutics, Inc. Inhibitors of nek7 kinase
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
KR20230052954A (ko) 2020-08-20 2023-04-20 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 점액 과다분비를 특징으로 하는 호흡기 질환의 치료 방법
US12324802B2 (en) 2020-11-18 2025-06-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022150173A1 (en) 2021-01-06 2022-07-14 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2022150174A1 (en) 2021-01-06 2022-07-14 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
JP2025505577A (ja) 2022-02-03 2025-02-28 バーテックス ファーマシューティカルズ インコーポレイテッド (6a,12a)-17-アミノ-12-メチル-6,15-ビス(トリフルオロメチル)-13,19-ジオキサ-3,4,18-トリアザトリシクロ[12.3.1.12,5]ノナデカ-1(18),2,4,14,16-ペンタエン-6-オールの調製方法及び結晶形態
IL314449A (en) 2022-02-03 2024-09-01 Vertex Pharma Methods of treatment for cystic fibrosis
WO2023154291A1 (en) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4525858A1 (en) 2022-05-16 2025-03-26 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN115806532A (zh) * 2022-08-31 2023-03-17 大连百傲化学股份有限公司 一种mit中杂质的制备方法
US20240158394A1 (en) 2022-09-14 2024-05-16 Halia Therapeutics, Inc. Nek7 inhibitors
CN115960100B (zh) * 2022-12-28 2023-08-18 北京康立生医药技术开发有限公司 一种治疗胃肠道间质瘤药物皮咪特昔布的合成方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833598A (en) * 1972-12-29 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine-6-carboxylic acids and esters
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
US20080275078A1 (en) * 2004-03-16 2008-11-06 Glaxo Group Limited Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors
AU2005251745A1 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
LT2502911T (lt) 2004-06-24 2017-09-11 Vertex Pharmaceuticals Incorporated Atp surišančios kasetės transporterių moduliatoriai
DE602005011286D1 (en) * 2004-07-05 2009-01-08 Astellas Pharma Inc Pyrazolopyridinderivate
US8362031B2 (en) * 2004-08-20 2013-01-29 University Of Kansas Lonidamine analogues and treatment of polycystic kidney disease
WO2008147952A1 (en) 2007-05-25 2008-12-04 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CA2705303A1 (en) * 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
CL2008003651A1 (es) 2007-12-10 2009-06-19 Novartis Ag Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias.
JP5637859B2 (ja) 2007-12-13 2014-12-10 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated 嚢胞性線維症膜コンダクタンスレギュレーターのモジュレーター
PT2358680E (pt) 2008-10-23 2013-05-14 Vertex Pharma Formas sólidas de n-(4-(7-azabiciclo[2.2.1]heptan-7-il)-2- (trifluorometil)fenil)-4-oxo- 5-(trifluorometil)-1,4- dihidroquinolina-3-carboxamida
EP2382197B1 (en) 2008-12-30 2016-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
PL2616444T3 (pl) * 2010-09-14 2016-04-29 Inst Biochemii I Biofizyki Pan Związki będące modulatorami zmutowanego białka CFTR oraz ich zastosowanie w leczeniu chorób związanych z zaburzeniami w funkcjonowaniu białka CFTR
DK2624695T3 (en) 2010-10-08 2016-01-04 Nivalis Therapeutics Inc NOVEL SUBSTITUTED quinoline-RELATIONS AS S-NITROSOGLUTATHIONREDUKTASEINHIBITORER
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
EP2760463B1 (en) 2011-09-20 2018-11-21 The University of North Carolina At Chapel Hill Regulation of sodium channels by plunc proteins
US9630929B2 (en) * 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
AU2013348018A1 (en) 2012-11-20 2015-06-04 Discoverybiomed, Inc. Small molecule CFTR correctors
EP2994463B1 (en) 2013-05-07 2017-10-25 Galapagos NV Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
HUE040366T2 (hu) 2013-08-08 2019-03-28 Galapagos Nv CFTR modulátor tieno[2,3-c]piránok
US9452986B2 (en) * 2014-02-06 2016-09-27 Abbvie Inc. 6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use
CA2942386A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
WO2015138934A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
MX366556B (es) 2014-10-31 2019-07-12 Abbvie Sarl Cromanos sustituidos y metodo de uso.
JP6615213B2 (ja) 2014-10-31 2019-12-04 アッヴィ・エス・ア・エール・エル 置換テトラヒドロピランおよび使用方法
US10130622B2 (en) * 2015-10-09 2018-11-20 Abbvie S.Á.R.L. Compounds for treatment of cystic fibrosis
RU2724345C2 (ru) * 2015-10-09 2020-06-23 Галапагос Нв N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ

Similar Documents

Publication Publication Date Title
JP2018529743A5 (https=)
RU2018115722A (ru) N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ
JP2018530557A5 (https=)
JP2025016684A5 (https=)
RU2484091C2 (ru) Производные изоксазоло-пиридина
JP2013526536A5 (https=)
JP2017510554A5 (https=)
JP2022548690A5 (https=)
RU2018123825A (ru) Соединения и способы для модуляции киназ, и показания для этого
HRP20210935T1 (hr) Spojevi 5-kloro-2-difluorometoksifenil pirazolopirimidina koji predstavljaju inhibitore jak
JP2016531874A5 (https=)
IL288243B1 (en) Heteroaryl-substituted pyridines and methods of use
CN111902141A (zh) 用于ikaros降解的羟脑苷脂结合剂
RU2012136643A (ru) [5,6]- гетероциклическое соединение
WO2021255212A1 (en) Braf degraders
JP2018500376A5 (https=)
JP2018524343A5 (https=)
JP2017506659A5 (https=)
JP2019523233A5 (https=)
TW201827428A (zh) 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JP2015522002A5 (https=)
HRP20190763T1 (hr) Spojevi pirazina za liječenje zaraznih bolesti
HRP20120457T1 (hr) 4-(4-cijano-2-tioaril)dihidropirimidinoni i njihova uporaba
JP2017519023A5 (https=)
CN108431002A (zh) 取代的吡唑并[3,4-b]吡啶-6-甲酸及其用途